Anavex Life Sciences Corp
Stock Watch
Stock Watch will tell you what changes at Anavex Life Sciences Corp.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 1.30 $ to 8.00 $ · Last price: 1.20 $ (As of: October 30, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 10/30/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Anavex Life Sciences Corp AVXL | 0.1 | – | -5.5 | – | – | – | -83.8 |
| Vertex Pharmaceuticals Inc VRTX | 141.4 | 33.3 | 25.7 | 55.0 | 38.1 | 9.6 | 33.1 |
| Regeneron Pharmaceuticals Inc REGN | 96.4 | 23.4 | 13.1 | 44.5 | 20.7 | 1.0 | 42.6 |
| Moderna Inc MRNA | 88.0 | – | 4.6 | -66.0 | -131.1 | -39.2 | 687.9 |
| argenx NV ARGX | 55.5 | 34.1 | 26.2 | 59.8 | 32.0 | 89.6 | 8.8 |
| BeiGene, Ltd. ONC | 41.9 | 66.1 | 33.8 | 88.9 | 19.1 | 40.2 | 18.0 |
| Revolution Medicines Inc RVMD | 39.8 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 225.0 |
| Royalty Pharma Plc RPRX | 37.0 | 36.4 | 20.8 | 95.8 | 100.3 | 5.1 | 85.4 |
| Genmab AS GMAB | 35.6 | 44.9 | 24.7 | 93.0 | 35.2 | -82.7 | 99.0 |
| Median of companies shown | 41.9 | 35.2 | 20.8 | 57.4 | 26.3 | 3.0 | 42.6 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -16 | -15 | -0.42 | -9 | 6 | 10 |
| 2017 | 0 | -16 | -13 | -0.33 | -9 | 24 | 28 |
| 2018 | 0 | -19 | -17 | -0.39 | -13 | 20 | 24 |
| 2019 | -1 | -29 | -26 | -0.54 | -19 | 20 | 25 |
| 2020 | 0 | -31 | -26 | -0.45 | -21 | 27 | 35 |
| 2021 | 0 | -42 | -38 | -0.54 | -30 | 151 | 162 |
| 2022 | 0 | -51 | -48 | -0.62 | -24 | 142 | 153 |
| 2023 | 0 | -48 | -47 | -0.60 | -28 | 142 | 154 |
| 2024 | 0 | -53 | -43 | -0.52 | -31 | 120 | 136 |
| 2025 | 0 | -51 | -46 | -0.54 | -39 | 95 | 104 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q3 | -0.14 | – | 0 | – | – | -7 | -7 |
| 2024: Q4 | -0.14 | – | 0 | – | – | -12 | -12 |
| 2025: Q1 | -0.13 | – | 0 | – | – | -6 | -6 |
| 2025: Q2 | -0.16 | – | 0 | – | – | -13 | -13 |
| 2025: Q3 | -0.11 | – | 0 | – | – | -9 | -9 |
| 2025: Q4 | -0.06 | – | 0 | – | – | -7 | -7 |
| 2026: Q1 | -0.06 | 53.80 | – | – | – | -4 | -4 |
| 2026: Q2 | 0.08 | 150.00 | – | – | – | -9 | -9 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 10 of our scanner strategies — each hit links to the scanner.
Momentum & Trend
Risk & Weakness
- Bankruptcy Study: Stacked Warning Signals
- Below the 50- & 200-SMA
- Downward Momentum
- Near 52-Week Low
- RS Weakness (≤10)
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
- Stan Weinstein: Stage 4B-
- Weakness Cluster
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 09/30/2027 | -0.55 | -0.55 – -0.55 | 0 | -66.7% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Anavex Life Sciences ist eine Biotech-Firma ohne Umsatz, die den Wirkstoff Blarcamesin (ANAVEX 2-73) gegen frühe Alzheimer-Demenz, Rett- und Fragiles-X-Syndrom entwickelt; sie verkauft keine KI-Produkte, und ihre Berichte nennen künstliche Intelligenz nicht als Bedrohung des Geschäfts. Belegt ist ein Einsatz in der Forschung: Laut Geschäftsbericht 10-K für das Geschäftsjahr 2025 wertete Anavex die Gen-Daten (DNA und RNA, mehr als 33.000 Gene) der Teilnehmer der Phase-2a-Studie mit einem datengetriebenen System für maschinelles Lernen und künstliche Intelligenz aus und leitete daraus Erbgut-Merkmale für die Auswahl von Patienten in späteren Studien ab. Nach der Vorrangregel (verkauft > bedroht > nutzt > neutral) ergibt das „nutzt“ — ein Analysewerkzeug in der klinischen Forschung, kein Umsatzbeitrag. Einschränkung: Die beschriebene Auswertung stammt aus dem Jahr 2018; im Quartalsbericht vom 28.08.2026 rät Anavex, sich bei Studienbeschreibungen nur noch auf diesen Bericht und künftige Angaben zu stützen, und dort taucht KI nicht auf.
View the full file — quotes, sources, reviewed filings
„More than 33,000 genes were analyzed using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA and RNA data in patients treated with ANAVEX ® 2-73."
Mehr als 33.000 Gene wurden mit einem unvoreingenommenen, datengetriebenen System für maschinelles Lernen und künstliche Intelligenz (KI) zur Auswertung von DNA- und RNA-Daten der mit ANAVEX 2-73 behandelten Patienten analysiert.
10-K · 2025-11-25 · View SEC filing
„The results from this evaluation supported the continued evaluation of genomic information in subsequent clinical trials, since these signatures can now be applied to neurological indications tested in future clinical trials with ANAVEX ® 2-73 including Alzheimer’s disease, Parkinson’s disease dementia and Rett syndrome."
Die Ergebnisse dieser Auswertung sprachen dafür, Erbgut-Informationen auch in späteren klinischen Studien weiter auszuwerten, da sich diese Merkmalsmuster nun auf neurologische Anwendungen übertragen lassen, die in künftigen Studien mit ANAVEX 2-73 geprüft werden, darunter Alzheimer, Parkinson-Demenz und das Rett-Syndrom.
10-K · 2025-11-25 · View SEC filing
Filings Reviewed: 10-Q (Q3 GJ 2026, Stichtag 30.06.2026) — keine KI-Erwähnung 2026-08-28 · 10-Q (Q2 GJ 2026, Stichtag 31.03.2026) — keine KI-Erwähnung 2026-08-28 · 10-K/A (GJ 2025) — keine KI-Erwähnung 2026-08-28 · 10-K (GJ 2025) — KI-gestützte Gen-Auswertung der Phase-2a-Studie 2025-11-25 · 10-K (GJ 2024) — gleichlautende Passage 2024-12-23
Rated on October 25, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 0.0%
- Share count grows by less than 3% a year 3.5%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 103 m net cash
- Operating cash flow covers the profits of the last three years 39 m
- Return on capital at 15% or higher, or up versus two years ago -54.2%
- Insiders hold at least 10% or are net buyers 3.1%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
0/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -48.9%
- ROCE > 15% -54.2%
- Expected return > 10% –
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
The company
About the Company
Anavex Life Sciences Corp. ist ein biopharmazeutisches Unternehmen.
- Employees
- 34
- Headquarters
- New York, NY
- Address
- 630 5th Avenue, 10111 New York, United States
- Phone
- 844 689 3939
- Website
- anavex.com
- IPO Date
- 08/02/2006
- ISIN
- US0327973006
- Stock Split
- 1:4 on 10/07/2015
Management
| Name | Title | Birth Year |
|---|---|---|
| Sandra Boenisch CPA, CGA | Principal Financial Officer & Treasurer | 1981 |
| Terrie Kellmeyer Ph.D. | Interim Chief Executive Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 10/20/2026 ANAVEX LIFE SCIENCES CORP. (AVXL): Other Events; Financial Statements and Exhibits SEC ↗
- 10/15/2026 ANAVEX LIFE SCIENCES CORP. (AVXL): Other Events; Financial Statements and Exhibits SEC ↗
- 09/28/2026 ANAVEX LIFE SCIENCES CORP. (AVXL): Changes in Control of Registrant; Submission of Matters to a Vote of Security Holders SEC ↗
- 09/09/2026 ANAVEX LIFE SCIENCES CORP. (AVXL): Other Events SEC ↗
- 09/02/2026 ANAVEX LIFE SCIENCES CORP. (AVXL): Other Events; Financial Statements and Exhibits SEC ↗
- 08/25/2026 ANAVEX LIFE SCIENCES CORP. (AVXL): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
- 08/17/2026 ANAVEX LIFE SCIENCES CORP. (AVXL): Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
- 08/11/2026 ANAVEX LIFE SCIENCES CORP. (AVXL): Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.